Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Adaptation of a RAS pathway activation signature from FF to FFPE tissues in colorectal cancer.

BMC medical genomics - 19 Oct 2016

Omolo Bernard, Yang Mingli, Lo Fang Yin, Schell Michael J, Austin Sharon, Howard Kellie, Madan Anup, Yeatman Timothy J

Abstract excerpt

BACKGROUND: The KRAS gene is mutated in about 40 % of colorectal cancer (CRC) cases, which has been clinically validated as a predictive mutational marker of intrinsic resistance to anti-EGFR inhibitor (EGFRi) therapy. Since nearly 60 % of patients with a wild type KRAS fail to respond to EGFRi combination therapies, there is a need to develop more reliable molecular signatures to better predict response. Here we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Neoplasms
Share to Formaldehyde

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Paraffin Embedding

Share to Proto-Oncogene Proteins B-raf

Share to ras Proteins

Share to Signal Transduction

Share to Tissue Fixation

Source

Open in PubMed Open full text

Identifiers

PMID: 27756306
DOI: 10.1186/s12920-016-0225-2
PMCID: PMC5069826

Genes

KRAS
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Adaptation of a RAS pathway activation signature from FF to FFPE tissues in colorectal cancer.PMID 27756306Read ↗

Transcriptome-Wide Analysis and Experimental Validation from FFPE Tissue Identifies Stage-Specific Gene Expression Profiles Differentiating Adenoma, Carcinoma In-Situ and Adenocarcinoma in Colorectal Cancer ProgressionSemantic proximity Read ↗

An Integrated RNA and DNA Molecular Signature for Colorectal Cancer ClassificationSemantic proximity Read ↗

Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal CancerSemantic proximity Read ↗

Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors.Semantic proximity Read ↗

Development of an APC and TP53-based duplex sequencing assay to positively predict colorectal cancer response to anti-EGFR therapy.Semantic proximity Read ↗

Pathway activation strength is a novel independent prognostic biomarker for cetuximab sensitivity in colorectal cancer patientsSemantic proximity Read ↗

Personalized targeted therapy prescription in colorectal cancer using algorithmic analysis of RNA sequencing data.Semantic proximity Read ↗

High-resolution detection of RPS24 microexon variations reveals novel splicing patterns in response to KRAS-targeted therapy in lung adenocarcinoma.Semantic proximity Read ↗

Proto-Oncogene HRAS Transcript Level and Overall Survival in Stages II and III Colorectal Cancer.Semantic proximity Read ↗

Comparison of Nanostring nCounter® Data on FFPE Colon Cancer Samples and Affymetrix Microarray Data on Matched Frozen TissuesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.